Physician profile
John Wilson
NPI 1689639270
$132,251.21
in general payments reported to CMS, 2019-2025
23 companies · $363 in 2025
The $363 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81K · 2020: $10K · 2021: $23K · 2022: $7,686 · 2023: $5,855 · 2024: $3,723 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Travel and Lodging: $3,254 · Food and Beverage: $2,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Travel and Lodging | $3,254.35 |
| Food and Beverage | $2,186.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $106,322.72 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16,550.49 | 2019-2024 | Lifevest |
| Canon Medical Systems USA, INC. | $3,971.77 | 2023-2025 | Interventional Angiography System, Ct Scanner |
| Pfizer INC. | $2,832.19 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $542.81 | 2019-2024 | |
| Amgen INC. | $454.82 | 2019-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $323.78 | 2019-2025 | Farxiga |
| Abbott Laboratories | $197.95 | 2021-2025 | Cardiomems, Pressurewire, Jot Dx |
| Medtronic, INC. | $192.02 | 2021-2024 | Corevalve Evolut R |
| Shockwave Medical, INC | $168.11 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $157.81 | 2019-2025 | Avvigo Guidance System |
| E.R. Squibb & Sons, L.L.C. | $94.41 | 2019-2024 | Eliquis, Camzyos |
| Edwards Lifesciences Corporation | $89.54 | 2024 | |
| Teleflex LLC | $63.22 | 2022-2023 | Supercross |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.42 | 2025 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $48.69 | 2019 | |
| Merz North America, INC. | $46.81 | 2025 | |
| Cleerly, INC. | $30.67 | 2023 | Cleerly Labs |
| Inspire Medical Systems, INC. | $24.00 | 2024 | Inspire |
| Merck Sharp & Dohme LLC | $23.94 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $23.40 | 2019 | |
| Impulse Dynamics (USA) INC. | $18.73 | 2024 | Optimizer |
| Amarin Pharma, INC. | $17.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.